Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
2.910
-0.530 (-15.41%)
Mar 31, 2025, 1:07 PM EDT - Market open

Company Description

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.

The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease.

It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs.

The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007.

Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Silence Therapeutics plc
Silence Therapeutics logo
Country United Kingdom
Founded 1994
Industry Biotechnology
Sector Healthcare
Employees 116
CEO Craig Tooman

Contact Details

Address:
72 Hammersmith Road
London, W14 8TH
United Kingdom
Phone 44 20 3457 6900
Website silence-therapeutics.com

Stock Details

Ticker Symbol SLN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001479615
CUSIP Number 82686Q101
ISIN Number US82686Q1013
SIC Code 2834

Key Executives

Name Position
Craig A. Tooman M.B.A. President, Chief Executive Officer and Executive Director
Rhonda L. Hellums Executive Vice President, Chief Financial Officer and Secretary
Dr. Steven J. Romano M.D. Executive Vice President and Chief Research and Development Officer
Dr. Marie Wikstrom Lindholm Ph.D. Chief Scientific Officer
Gem Gokmen Hopkins Head of IR and Corporate Communications
Gianine Esposito Chief Human Resources Officer
Dr. Barbara A. Ruskin J.D., Ph.D. Senior Vice President and Chief Intellectual Property and Innovation Officer
Dr. Eric Floyd M.B.A., M.S., Ph.D. Senior Vice President of Regulatory Affairs and Quality Assurance
J.P. Gabriel Chief Technical Operations Officer
Curtis Rambaran M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Feb 27, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G Filing
Feb 11, 2025 SCHEDULE 13G/A Filing
Jan 2, 2025 8-K Current Report
Dec 20, 2024 SCHEDULE 13D/A Filing
Dec 9, 2024 6-K Report of foreign issuer
Nov 18, 2024 6-K Report of foreign issuer
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals